MOTS-c: A Mitochondrial Peptide, Not a GH Secretagogue

The short version

MOTS-c is a 16-amino-acid peptide encoded inside mitochondrial DNA — not by the nuclear genome that makes most proteins in the body — inside the gene for a mitochondrial ribosomal RNA. It does not touch the growth-hormone-releasing-hormone receptor or the ghrelin receptor that the other two compounds on this desk act through. Its best-characterized action is inhibiting an enzyme pathway (the folate cycle) inside cells, which activates AMPK, a master regulator of cellular energy that improves glucose handling, mainly in skeletal muscle.

This desk includes MOTS-c as the metabolic end of the growth-hormone-axis story, not as another way of raising GH. The evidence base is also categorically different from the other two pages: every claim about what exogenous MOTS-c does comes from cell-culture and animal experiments — mostly mice — plus one modest human cohort study measuring a biomarker association, not an interventional trial of the peptide itself. There is no published human dose-response data for MOTS-c at all.

What it is

MOTS-c is a 16-amino-acid peptide (sequence MRWQEMGYIFYPRKLR) encoded not by the cell's nuclear DNA but by a short open reading frame inside the mitochondrial 12S ribosomal RNA gene, MT-RNR1. It belongs to a small class of 'mitochondrial-derived peptides' discovered by searching mitochondrial DNA for previously unrecognized coding sequences. The sequence is highly conserved across mammalian species, which is often read as a sign of functional importance, though conservation alone does not establish what the peptide does in humans specifically.

How it works

MOTS-c's best-characterized action is inhibiting the folate cycle, a metabolic pathway involved in building purines (components of DNA and RNA); this inhibition raises a molecule called AICAR, which activates AMP-activated protein kinase, or AMPK — a master regulator of cellular energy balance — primarily in skeletal muscle ^[15]. Under metabolic stress, MOTS-c has also been shown to move from the mitochondrion into the cell nucleus, where it helps regulate nuclear gene expression in an AMPK-dependent manner, including antioxidant-response genes through an interaction with the transcription factor NRF2 ^[14] — the first demonstrated case of a mitochondrial-encoded peptide signaling to the nucleus this way. A 2024 study went further, identifying casein kinase 2 (CK2) as a direct binding partner of MOTS-c, with tissue-specific effects — activating CK2 in muscle while suppressing it in fat — proposed to underlie MOTS-c's effects on muscle glucose uptake and its prevention of muscle atrophy in mice ^[10].

What the research shows

Seven sources make up the cited evidence for MOTS-c, and the pattern is stark: six describe mouse, rat, or isolated-cell experiments, and only one involves living human subjects — and that one measures an existing biomarker, not the effect of giving anyone the peptide.

The founding 2015 paper identified MOTS-c, characterized its folate-cycle/AMPK mechanism, and showed that MOTS-c treatment prevented age-related and high-fat-diet-induced insulin resistance and obesity in mice ^[15]. A 2018 follow-up, in human and mouse cell lines (not whole organisms), demonstrated the stress-induced nuclear translocation and NRF2 interaction described above ^[14]. A 2021 study found that exercise induces the body's own MOTS-c production, and that giving mice exogenous MOTS-c significantly improved treadmill running capacity, grip strength, and gait — most notably in aged mice around 22 to 23.5 months old — framing MOTS-c as a candidate 'exercise-mimetic' ^[13]. A 2023 review consolidates this mechanism and indication-spanning animal and cell evidence into the field's current reference frame ^[12], and is cited here as a synthesis, not as new primary data. The 2024 CK2-binding study, discussed above, combined cell-free assays with experiments in young, aged, high-fat-diet, and immobilized mice ^[10]. A 2025 study in a rat model of type 2 diabetes found MOTS-c treatment increased mitochondrial respiration in heart tissue and was associated with lower fasting glucose and less cardiac enlargement ^[16].

The single human study is a 2024 multicenter cohort of 94 chronic hemodialysis patients, followed for a median of 26.5 months, in which naturally circulating MOTS-c levels were independently associated with a composite of death and cardiovascular events, modestly improving a risk-prediction model's discrimination (area under the curve rising from 0.727 to 0.743) ^[11]. That association reached only borderline statistical significance (hazard ratio 1.004, p=0.05) in a single, severely ill population, and it says nothing about what happens when MOTS-c is administered to anyone, sick or healthy.

Reported effects, cautions & safety

Unlike CJC-1295 and the CJC-1295/ipamorelin combination, MOTS-c has not accumulated a body of user-reported effects on peptide forums and clinic blogs at anything like the same scale — research-use community discussion of it exists, but this desk found no substantial, citable pattern of self-reported benefits or side effects worth summarizing here, and it will not invent one. What follows instead are cautions drawn from the same preclinical and observational literature summarized above.

Cautions:

• No human efficacy trial exists. Every claim about MOTS-c improving metabolism, exercise capacity, or aging comes from mouse or rat studies ^[13][15][16], or from isolated human cells in a dish ^[14]. The single study involving living human subjects ^[11] measured an existing biomarker association in ill patients, not the effect of giving anyone the peptide.
• No validated human pharmacokinetics. There is no published measured human half-life, bioavailability, or dose-response for MOTS-c; the mouse and rat doses used in the cited studies ^[13][15][16] (milligrams per kilogram, daily) cannot be responsibly scaled to a human dose, and this desk does not attempt to.
• Unregulated research-chemical status. MOTS-c is not approved by the FDA for any human use and is sold only for laboratory research; purity, identity, and sterility are not regulated the way a pharmaceutical would be, and vary by supplier.
• Treated as prohibited in elite sport. Anti-doping authorities classify MOTS-c among peptide and metabolic-modulator agents prohibited at all times; athletes risk sanctions for use regardless of the thinness of the human evidence.
• Small, single-population human data. The one MOTS-c human-subjects study behind this page followed 94 chronic hemodialysis patients ^[11] — a specific, severely ill population — with an association that reached only borderline statistical significance (p=0.05); it should not be read as evidence about healthy adults.
• A genetic and population wrinkle. At least one MOTS-c gene variant appears pro-diabetogenic in some populations, and exercise responses attributed to MOTS-c differ by ancestry in animal and biomarker work — a reminder that whatever this peptide does, it may not do it uniformly.

Where it fits in the GH axis

MOTS-c is the lead compound on this desk for a specific reason: it marks where 'growth hormone axis research' stretches into adjacent metabolic territory without sharing a receptor with CJC-1295 or CJC-1295/ipamorelin. Where those two peptides try to increase GH output at the pituitary, MOTS-c works downstream and independently, on cellular energy sensing and insulin sensitivity — a genuinely different research question that happens to sit in the same practical neighborhood as GH-axis metabolism. It is also, by a wide margin, the least clinically tested of the three. See the comparison page for exactly how the evidence bases diverge.